Immunovant Liabilities And Stockholders Equity from 2010 to 2024
| IMVT Stock | USD 26.89 0.02 0.07% |
Liabilities And Stockholders Equity | First Reported 2019-03-31 | Previous Quarter 589.7 M | Current Value 515.7 M | Quarterly Volatility 189.8 M |
Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 34.8 M or Other Operating Expenses of 296.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.8 K. Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules.
Immunovant | Liabilities And Stockholders Equity |
Latest Immunovant's Liabilities And Stockholders Equity Growth Pattern
Below is the plot of the Liabilities And Stockholders Equity of Immunovant over the last few years. It is the total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation. Immunovant's Liabilities And Stockholders Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunovant's overall financial position and show how it may be relating to other accounts over time.
| Liabilities And Stockholders Equity | 10 Years Trend |
|
Liabilities And Stockholders Equity |
| Timeline |
Immunovant Liabilities And Stockholders Equity Regression Statistics
| Arithmetic Mean | 166,675,342 | |
| Geometric Mean | 6,169,126 | |
| Coefficient Of Variation | 142.49 | |
| Mean Deviation | 207,162,856 | |
| Median | 405,000 | |
| Standard Deviation | 237,487,442 | |
| Sample Variance | 56400.3T | |
| Range | 666M | |
| R-Value | 0.82 | |
| Mean Square Error | 19561T | |
| R-Squared | 0.68 | |
| Significance | 0.0002 | |
| Slope | 43,724,418 | |
| Total Sum of Squares | 789604T |
Immunovant Liabilities And Stockholders Equity History
About Immunovant Financial Statements
Immunovant shareholders use historical fundamental indicators, such as Liabilities And Stockholders Equity, to determine how well the company is positioned to perform in the future. Although Immunovant investors may analyze each financial statement separately, they are all interrelated. The changes in Immunovant's assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunovant's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Liabilities And Stockholders Equity | 666.4 M | 386.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.